Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Are haploidentical donors the alternative donors of choice?

Nicolaus Kröger • 25 Oct 2019
COSTEM 2019
Leukemia Cyclophosphamide

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, describes haploidentical donors and discusses to what extent they are a suitable choice for transplant. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals